Understanding Pediatric Exclusivity Extension Vouchers |…

What is a Pediatric Exclusivity Extension Voucher?

A pediatric exclusivity extension voucher, often referred to as a PEEV, is a regulatory tool designed to incentivize pharmaceutical companies to conduct and complete pediatric studies for new drugs. This voucher can be used by the holder to extend the market exclusivity period of their own drug or transfer it to another company in exchange for compensation.

The voucher system aims to address the lack of pediatric data for many medicines, which is crucial for ensuring that children receive safe and effective treatments tailored to their specific needs.

Requirements and Process

To obtain a PEEV, pharmaceutical companies must submit an application to the regulatory authority, typically the FDA in the United States. The application includes detailed information about the pediatric studies conducted, such as study design, methodology, and results. The company must demonstrate that the studies were completed successfully and provide evidence of their clinical significance.

Once approved, the voucher can be used within a specified timeframe to extend the market exclusivity period for another drug or transferred to another entity through an agreement.

live demo · related simulation● LIVE

Why It Matters

The PEEV system is crucial for advancing pediatric research and ensuring that children have access to safe and effective medications. By incentivizing companies to conduct these studies, the voucher program helps fill critical gaps in pediatric drug development.

Moreover, it encourages innovation by providing a tangible benefit for companies willing to invest in pediatric research, ultimately benefiting public health.

Real-World Examples

The PEEV system has been successfully implemented and utilized in various cases. For instance, the voucher was used by AbbVie to extend the exclusivity period for their drug Venclexta, which is used to treat certain types of leukemia.

Another example includes the transfer of a PEEV from Pfizer to Amgen for use on their drug Neulasta, demonstrating how this tool can be leveraged across different companies and products.

Frequently asked questions

Who is eligible to apply for a pediatric exclusivity extension voucher?

Eligibility typically requires that the company has completed successful pediatric studies as part of their regulatory application process. The specific criteria can vary by country, but generally, companies must demonstrate compliance with all relevant regulations and standards.

How long does it take to receive a PEEV after submitting an application?

The timeline for receiving a PEEV varies depending on the regulatory authority's review process. In the United States, the FDA aims to make a decision within 90 days of receiving a complete application, but this can extend based on the complexity and thoroughness of the submitted data.

Can a PEEV be used for any type of drug or only specific ones?

A PEEV is generally not limited to specific types of drugs. However, it must be applied for in relation to a particular product and can only extend the market exclusivity period for that specific drug.

What happens if a company does not use their PEEV within the specified timeframe?

If a company fails to use their PEEV by the expiration date, it becomes invalid. However, companies can transfer the voucher to another entity through an agreement, allowing for its continued use in extending market exclusivity.

Try it live

Everything above runs in your browser — open Pediatric Exclusivity Extension Voucher Simulator and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.

▶ Open Pediatric Exclusivity Extension Voucher Simulator simulation